Corrigendum to "Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies" [Breast 41S1 (2018) S11–12]. (February 2020) - Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope S.; Castrellon, Aurelio; Joy, Anil Abraham; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana Theall, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; et al.